XERS - Xeris Pharmaceuticals Inc Stock Price, Fair Value and News

$6.73+0.26 (+4.02%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

XERS Price Action

Last 7 days

-6.3%

Last 30 days

-32.0%

Last 90 days

-14.7%

Trailing 12 Months

96.8%

XERS RSI Chart

XERS Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-71.4

Price/Sales (Trailing)

4.2

Price/Free Cashflow

105.77

XERS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

XERS Fundamentals

XERS Revenue

Revenue (TTM)

266.1M

Rev. Growth (Yr)

37.06%

Rev. Growth (Qtr)

3.97%

XERS Earnings

Earnings (TTM)

-15.6M

Earnings Growth (Yr)

103.95%

Earnings Growth (Qtr)

132.21%

XERS Profitability

Return on Equity

1.8K%

Return on Assets

-4.22%

Free Cashflow Yield

0.95%

XERS Investor Care

Shares Dilution (1Y)

11.30%

Diluted EPS (TTM)

-0.09

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	222.6M	246.0M	266.1M	0
2024	171.4M	181.4M	187.4M	203.1M
2023	121.4M	134.1M	152.7M	163.9M
2022	63.5M	79.9M	98.5M	110.2M
2021	27.7M	35.0M	42.3M	49.6M
2020	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Xeris Pharmaceuticals Inc

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

CEO	Mr. Paul R. Edick
WEBSITE	xerispharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	355

Xeris Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Xeris Pharmaceuticals Inc? What does XERS stand for in stocks?

XERS is the stock ticker symbol of Xeris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xeris Pharmaceuticals Inc (XERS)?

As of Wed Dec 03 2025, market cap of Xeris Pharmaceuticals Inc is 1.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XERS stock?

You can check XERS's fair value in chart for subscribers.

Is Xeris Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XERS is over valued or under valued. Whether Xeris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xeris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XERS.

What is Xeris Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, XERS's PE ratio (Price to Earnings) is -71.4 and Price to Sales (PS) ratio is 4.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XERS PE ratio will change depending on the future growth rate expectations of investors.